Answers are grounded in this paper and cite their sources.
Glioblastoma (GBM), the most aggressive adult primary brain tumor, faces lethal challenges due to its immunosuppressive microenvironment and blood-brain barrier (BBB) impedance. This study investigates how cRGD-functionalized macrophage-derived extracellular vesicles (cEV) loaded with the Liver X receptor (LXR) antagonist GSK2033 (cEV@GSK) enhance T cell-mediated antitumor immunity in GBM by targeting the LXR/ATP-binding cassette transporter A1 (Abca1) axis. Methods include isolating and cRGD-functionalizing RAW264.7 macrophage-derived extracellular vesicles, loading GSK2033 to form cEV@GSK, characterizing nanoparticles via TEM, size/zeta potential, and HPLC; evaluating BBB penetration, cellular uptake, and cytotoxicity in vitro; assessing in vivo distribution, antitumor efficacy, and biosafety using an orthotopic GBM mouse model; and analyzing mechanisms via proteomics and single-cell RNA sequencing (scRNA-seq), with T cell-LLM-GL261 co-cultures validating KLRB1 function. Results show cEV@GSK effectively crosses the BBB, exhibits biosafety, and significantly suppresses tumor growth. Mechanistically, it blocks the LXR/Abca1 axis, reducing myelin lipid transfer from lipid-laden macrophages (LLMs) and downregulating T cell KLRB1, thereby augmenting T cell activation and antitumor activity. Conclusion: cEV@GSK enhances T cell immunity by disrupting the LXR/Abca1 axis and LLM-mediated lipid transfer, offering a novel GBM immunotherapy strategy. Schematic illustration of the proposed molecular mechanism by which cEV@GSK blocks the LXR/Abca1 axis reduces myelin lipid transfer by LLMs, downregulates KLRB1 expression, and enhances T cell-mediated antitumor immunity in the treatment of GBM.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: